Skip to content

Effectiveness of probiotic supplementation in pneumonia treatment in Vietnamese children

The effectiveness of probiotic as adjuvant therapy of pneumonia in children in Vietnam: a randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN99078944
Enrollment
300
Registered
2025-12-17
Start date
2026-09-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric patients with pneumonia Respiratory

Interventions

Children will be randomly assigned to one of two groups in a 1:1 ratio. The intervention group will receive standard antibiotic treatment plus oral probiotics. The control group will receive standard

Sponsors

Hung Yen Provincial People’s Committee
Lead Sponsor
Hung Yen Provincial Department of Science and Technology
Collaborator
Thai Binh Pediatrics Hospital
Collaborator

Eligibility

Sex/Gender
All
Age
2 Months to 16 Years

Inclusion criteria

Inclusion criteria: 1. A confirmed diagnosis of pneumonia at any severity level. 2. CRP testing performed to determine the indication for antibiotic therapy according to the study protocol. Only children with CRP =30 mg/dL were eligible for inclusion. 3. Written informed consent obtained from the family after full explanation of the study objectives, potential benefits, risks, and participants’ rights; consent signed by a parent or legal caregiver.

Exclusion criteria

Exclusion criteria: 1. Contraindications to probiotics, including allergy or hypersensitivity to any component of the probiotic preparation. 2. Severe immunodeficiency or congenital immunological disorders. 3. Use of probiotics, probiotic supplements, or products with similar components prior to hospital admission, which may confound the assessment of the intervention’s effectiveness. 4. Presence of severe underlying conditions or the need for special treatment regimens, such as: cancer receiving chemotherapy or radiotherapy, hepatic failure, advanced renal failure, severe cyanotic congenital heart disease requiring surgery, or other life-threatening conditions requiring intensive care. 5. Inability to ensure complete in-hospital follow-up, for example: likelihood of early referral, transfer to another facility, or discharge within 48 hours of admission. 6. Lack of cooperation with necessary procedures for treatment evaluation, such as blood sampling for laboratory tests.

Countries

Viet Nam

Contacts

Public ContactTrong Kiem Tran
kiemthuytb@gmail.com+84 (0)983081038

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026